Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary collaboration to co-develop and market the product in 2Q17, which became a definitive agreement later in the year.
Three Phase III studies are underway with the HA/NSAID formulation, including:
This confirmatory study in the knee
A study of OA in the shoulder, elbow, hip and ankle
A long-term study in OA patients to evaluate safety
This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 440 patients with knee OA. ONO-5704/SI-613 demonstrated a statistically significant improvement in knee pain scores vs. placebo at 12 weeks after the initial injection, with no major safety concerns observed in the ONO-5704/SI-613 group. Ono and Seikagaku plan to file for manufacturing and marketing approval in 1H20, after evaluation of data from all three studies.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary...
Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary collaboration to co-develop and market the product in 2Q17, which became a definitive agreement later in the year.
Three Phase III studies are underway with the HA/NSAID formulation, including:
This confirmatory study in the knee
A study of OA in the shoulder, elbow, hip and ankle
A long-term study in OA patients to evaluate safety
This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 440 patients with knee OA. ONO-5704/SI-613 demonstrated a statistically significant improvement in knee pain scores vs. placebo at 12 weeks after the initial injection, with no major safety concerns observed in the ONO-5704/SI-613 group. Ono and Seikagaku plan to file for manufacturing and marketing approval in 1H20, after evaluation of data from all three studies.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
